For many people with advanced lung cancer, the goal is to keep the disease under control for as long as possible. Standard chemotherapy is a common way to fight cancer, but it often makes people feel very sick. One major side effect is a drop in white blood cells, which are the body's main defense against infection. When these counts get too low, patients face serious risks. This study looked at whether giving a specific medicine called recombinant human granulocyte colony-stimulating factor, or rhG-CSF, could help fix this problem before it gets too bad. This drug is designed to tell the bone marrow to make more white blood cells quickly.
The researchers worked at The Third People's Hospital of Yuhang District. They took 150 patients who were about to start platinum-based doublet chemotherapy. This is a standard treatment that uses two different drugs to attack cancer. The patients were split into two groups. One group received the rhG-CSF injection within 24 to 72 hours after their chemotherapy session. The other group did not get this extra drug and was simply observed to see how their bodies reacted to the chemo alone.
After the treatment, the team measured many things to see how the two groups compared. They found that the group getting the extra drug had significantly higher levels of white blood cells and neutrophils. These are the cells that fight infection. They also saw improvements in immune function markers. Perhaps most importantly, the group with the drug had a higher objective response rate, meaning 44 percent of them showed a clear shrinkage in their tumors compared to only 26.7 percent in the group without the drug. The disease control rate was also much better, with 88 percent of patients in the drug group having stable or shrinking disease versus 64 percent in the other group.
The study also checked for safety. They looked at inflammatory factors like IL-6 and TNF-alpha, which are chemicals the body releases during stress or infection. The group getting the drug had lower levels of these chemicals, suggesting less inflammation. The researchers did not report any serious safety concerns, discontinuations, or issues with how well the patients tolerated the extra injections. This suggests the drug was generally well-tolerated in this specific setting.
Despite these promising numbers, there are important reasons not to celebrate too loudly. This study only included 150 people from a single hospital in China. We do not know if these results will hold true for patients in other countries or with different types of lung cancer. The study did not report a primary outcome, which is usually the main reason a trial is run, and the follow-up time was not reported. Because the evidence comes from just one small study, it is too early to say this should become standard practice everywhere. Patients should talk to their oncologist about their specific situation before making any changes to their treatment plan.
